HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (1- (4- methoxybenzenesulfonyl)- 2,3- dihydro- 1H- indol- 7- yl)- 1- oxyisonicotinamide

an antineoplastic agent that target microtubules; structure in first source

Also Known As:

MPT0B271

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Nicotinic Acids: 13
      - Niacinamide: 2223
        N-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)-1-oxyisonicotinamide: 1
- Heterocyclic Acids
  - Nicotinic Acids: 13
    - Niacinamide: 2223
      - N-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)-1-oxyisonicotinamide: 1
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - N-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)-1-oxyisonicotinamide: 1
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - N-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)-1-oxyisonicotinamide: 1

Experts

1.	Chang, J-Y: 1 article (04/2014)
2.	Hsiao, C-J: 1 article (04/2014)
3.	Liou, J-P: 1 article (04/2014)
4.	Pai, H-C: 1 article (04/2014)
5.	Pan, S-L: 1 article (04/2014)
6.	Teng, C-M: 1 article (04/2014)
7.	Tsai, A-C: 1 article (04/2014)
8.	Wang, C-Y: 1 article (04/2014)
9.	Wang, J-C: 1 article (04/2014)

Related Diseases

1.	Neoplasms (Cancer) 04/10/2014 - "These findings identify MPT0B271 as a promising new tubulin-binding compound for the treatment of various cancers. " 04/10/2014 - "MPT0B271 reduced cell growth and viability at nanomolar concentrations in numerous cancer cell lines, including a multidrug-resistant cancer cell line NCI/ADR-RES. Further studies indicated that MPT0B271 is not a substrate of P-glycoprotein (P-gp), as determined by flow cytometric analysis of rhodamine-123 (Rh-123) dye efflux and the calcein acetoxymethyl ester (calcein AM) assay. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/10/2014 - "Finally, this study demonstrated that MPT0B271 in combination with erlotinib significantly inhibits the growth of the human non-small cell lung cancer A549 cells as compared with erlotinib treatment alone, both in vitro and in vivo. " 04/10/2014 - "Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib."

Related Drugs and Biologics

1.	Member 1 Subfamily B ATP Binding Cassette Transporter
2.	Coloring Agents (Dyes)
3.	Erlotinib Hydrochloride (CP 358,774)
4.	calcein AM
5.	Tubulin